{"transactions":[{"id":1223366,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CLO and Secretary"}}],"security":"Stock Option  (right to buy)","published_at":"2025-03-05T21:23:28.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":1529,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":1529,"derivative":{"exercise_price":243.53,"expiration_date":"2035-03-03","underlying":"Common Stock","underlying_shares":1529},"source":{"system":"sec-edgar","filing":"0001735276-25-000035","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000035/edgardoc.xml","form_type":"4"}},{"id":1223365,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CLO and Secretary"}}],"security":"Common Stock","published_at":"2025-03-05T21:23:28.000Z","date":"2025-03-03","kind":"grant","planned":false,"acquired":true,"shares":757,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":8002,"source":{"system":"sec-edgar","filing":"0001735276-25-000035","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527625000035/edgardoc.xml","form_type":"4"}},{"id":1392438,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, CLO and Secretary"}}],"security":"Common Stock","published_at":"2024-10-03T20:11:52.000Z","date":"2024-10-01","kind":"grant","planned":false,"acquired":true,"shares":7245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock.  The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date."}],"balance_after":7245,"source":{"system":"sec-edgar","filing":"0001735276-24-000096","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527624000096/edgardoc.xml","form_type":"4"}},{"id":1941645,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2023-03-22T20:47:41.000Z","date":"2023-03-20","kind":"sale","planned":false,"acquired":false,"shares":4410,"price":7.76,"value":34221.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.58 to $7.94, inclusive. The Reporting Person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":102200,"source":{"system":"sec-edgar","filing":"0001104659-23-035638","document":"tm2310223-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923035638/tm2310223-1_4seq1.xml","form_type":"4"}},{"id":1999836,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2023-02-23T01:58:28.000Z","date":"2023-02-17","kind":"sale","acquired":false,"shares":3297,"price":7.45,"value":24562.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the Reporting Person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2023. The Reporting Person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.34 to $7.58, inclusive. The Reporting Person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":106610,"source":{"system":"sec-edgar","filing":"0001104659-23-024424","document":"tm237526-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923024424/tm237526-5_4seq1.xml","form_type":"4"}},{"id":2013557,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2023-02-15T21:52:12.000Z","date":"2023-02-13","kind":"sale","acquired":false,"shares":2868,"price":7.67,"value":21997.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2023. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2023. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.42 to $7.79, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":109907,"source":{"system":"sec-edgar","filing":"0001104659-23-022429","document":"tm236923-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923022429/tm236923-1_4seq1.xml","form_type":"4"}},{"id":2050831,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2023-01-19T21:57:23.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":792,"price":10.34,"value":8189.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.19 to $10.75, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":112775,"source":{"system":"sec-edgar","filing":"0001104659-23-005053","document":"tm233882-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923005053/tm233882-3_4seq1.xml","form_type":"4"}},{"id":2050830,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2023-01-19T21:57:23.000Z","date":"2023-01-17","kind":"sale","acquired":false,"shares":1396,"price":9.57,"value":13359.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 13, 2023. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.19 to $10.18, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":113567,"source":{"system":"sec-edgar","filing":"0001104659-23-005053","document":"tm233882-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465923005053/tm233882-3_4seq1.xml","form_type":"4"}},{"id":2302523,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2022-04-06T20:34:04.000Z","date":"2022-04-04","kind":"sale","acquired":false,"shares":2786,"price":8.25,"value":22984.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.60, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":114963,"source":{"system":"sec-edgar","filing":"0001104659-22-043244","document":"tm2212086-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922043244/tm2212086-1_4seq1.xml","form_type":"4"}},{"id":2320048,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2022-03-23T22:39:37.000Z","date":"2022-03-21","kind":"sale","acquired":false,"shares":58,"price":8.68,"value":503.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.695, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":117749,"source":{"system":"sec-edgar","filing":"0001104659-22-037153","document":"tm2210284-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922037153/tm2210284-3_4seq1.xml","form_type":"4"}},{"id":2320047,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2022-03-23T22:39:37.000Z","date":"2022-03-21","kind":"sale","acquired":false,"shares":4897,"price":8.29,"value":40596.13,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $8.655, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":117807,"source":{"system":"sec-edgar","filing":"0001104659-22-037153","document":"tm2210284-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922037153/tm2210284-3_4seq1.xml","form_type":"4"}},{"id":2382221,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2022-02-22T21:37:25.000Z","date":"2022-02-17","kind":"sale","acquired":false,"shares":4100,"price":3.55,"value":14555.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 16, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.49 to $3.67, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":122704,"source":{"system":"sec-edgar","filing":"0001104659-22-025672","document":"tm227228-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922025672/tm227228-2_4seq1.xml","form_type":"4"}},{"id":2394484,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2022-02-15T21:42:10.000Z","date":"2022-02-11","kind":"sale","acquired":false,"shares":3252,"price":3.36,"value":10926.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2022. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.30 to $3.43, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":126804,"source":{"system":"sec-edgar","filing":"0001104659-22-023834","document":"tm226802-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922023834/tm226802-2_4seq1.xml","form_type":"4"}},{"id":2433790,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-19T01:06:10.000Z","date":"2022-01-13","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, January 13, 2022. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service."}],"balance_after":120000,"derivative":{"exercise_price":2.85,"expiration_date":"2032-01-13","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001104659-22-005022","document":"tm223208-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922005022/tm223208-1_4seq1.xml","form_type":"4"}},{"id":2433789,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2022-01-19T01:06:10.000Z","date":"2022-01-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under an aggregate of 20,000 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 13, 2022. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service."}],"balance_after":130056,"source":{"system":"sec-edgar","filing":"0001104659-22-005022","document":"tm223208-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465922005022/tm223208-1_4seq1.xml","form_type":"4"}},{"id":2754338,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2021-04-07T21:44:52.000Z","date":"2021-04-05","kind":"sale","acquired":true,"shares":3292,"price":4.95,"value":16295.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2021. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."}],"balance_after":110056,"source":{"system":"sec-edgar","filing":"0001104659-21-047689","document":"tm2112333-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465921047689/tm2112333-1_4seq1.xml","form_type":"4"}},{"id":2774801,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2021-03-23T20:11:35.000Z","date":"2021-03-19","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service."}],"balance_after":113348,"source":{"system":"sec-edgar","filing":"0001104659-21-040307","document":"tm2110581-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465921040307/tm2110581-3_4seq1.xml","form_type":"4"}},{"id":2850216,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T21:57:06.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 16, 2021. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service."}],"balance_after":68000,"derivative":{"exercise_price":7.33,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001104659-21-025273","document":"tm217191-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465921025273/tm217191-2_4seq1.xml","form_type":"4"}},{"id":2850215,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2021-02-18T21:57:06.000Z","date":"2021-02-16","kind":"grant","acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under an aggregate of 34,000 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 16, 2021. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service."}],"balance_after":83348,"source":{"system":"sec-edgar","filing":"0001104659-21-025273","document":"tm217191-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465921025273/tm217191-2_4seq1.xml","form_type":"4"}},{"id":2859078,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2021-02-16T21:08:46.000Z","date":"2021-02-11","kind":"sale","acquired":false,"shares":3186,"price":7.55,"value":24054.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":49348,"source":{"system":"sec-edgar","filing":"0001104659-21-023939","document":"tm216891-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465921023939/tm216891-2_4seq1.xml","form_type":"4"}},{"id":3180658,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2020-04-07T21:24:12.000Z","date":"2020-04-03","kind":"sale","acquired":false,"shares":3091,"price":8.51,"value":26304.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2020.  The reporting person structured the durable automatic sales instructions to constitute a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1.  The sales do not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.52, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":52534,"source":{"system":"sec-edgar","filing":"0001104659-20-044247","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465920044247/a4.xml","form_type":"4"}},{"id":3277075,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-12T23:20:51.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 10, 2020. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service."}],"balance_after":55000,"derivative":{"exercise_price":12.96,"expiration_date":"2030-02-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-20-019455","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/a4.xml","form_type":"4"}},{"id":3277074,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2020-02-12T23:20:51.000Z","date":"2020-02-10","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of common stock issuable under an aggregate of 27,500 restricted stock units (\"RSUs\") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the \"Plan\"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 10, 2020. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service."}],"balance_after":55625,"source":{"system":"sec-edgar","filing":"0001104659-20-019455","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465920019455/a4.xml","form_type":"4"}},{"id":3564990,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-04T01:28:24.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":168750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the \"Company\"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Vesting Commencement Date of the option is April 1, 2019. The option vests over four years, with 25% of the shares of Common Stock underlying the option vesting upon the one-year anniversary of the Vesting Commencement Date and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable option agreement."}],"balance_after":168750,"derivative":{"exercise_price":19.79,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":168750},"source":{"system":"sec-edgar","filing":"0001104659-19-019772","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/a4.xml","form_type":"4"}},{"id":3564989,"issuer":{"id":6271,"kind":"organization","name":"Voyager Therapeutics, Inc."},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP & General Counsel"}}],"security":"Common Stock","published_at":"2019-04-04T01:28:24.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":28125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This equity award was not granted pursuant to any pre-existing equity incentive plan of Voyager Therapeutics, Inc. (the \"Company\"), but rather was granted as an inducement material to the Reporting Person entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock underlying one or more restricted stock unit (\"RSU\") awards.  Each RSU represents the right to receive one share of common stock, par value $0.001 per share, of the Company (the \"Common Stock\") upon vesting, subject to the Reporting Person's continued employment by the Company and other terms and conditions set forth in the applicable RSU agreement.  The RSU awards vest over three years, with 33.33% of the shares of Common Stock underlying the award vesting upon the one-year anniversary of the vesting commencement date (the \"Vesting Commencement Date\") of such award and the remainder vesting in equal annual installments thereafter. The Vesting Commencement Date of this RSU award is April 1, 2019."}],"balance_after":28125,"source":{"system":"sec-edgar","filing":"0001104659-19-019772","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1640266/000110465919019772/a4.xml","form_type":"4"}},{"id":3854988,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-08-02T16:06:48.000Z","date":"2018-07-31","kind":"other","acquired":false,"shares":28709,"price":137,"value":3933133.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Foundation Medicine, Inc., a Delaware corporation (the \"Company\") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the \"Merger Agreement\"), with Roche Holdings, Inc., a Delaware corporation (\"Parent\" or \"Roche\"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the \"Tender Offer\") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company."},{"field":"shares","element":"transactionShares","label":"F3","text":"The amount reported represents the number of unvested restricted stock units cancelled in connection with the Tender Offer by Roche and converted into the right to receive an amount in cash equal to the product of (1) the offer price of $137 per share multiplied by (2) the number of shares represented by such unvested restricted stock units, without interest and less any required withholding taxes. Payments are subject to the original vesting schedule and vesting conditions applicable to the underlying unvested restricted stock units."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-044926","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118044926/doc4.xml","form_type":"4"}},{"id":3854987,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-08-02T16:06:48.000Z","date":"2018-07-31","kind":"other","acquired":false,"shares":76494,"price":137,"value":10479678.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Foundation Medicine, Inc., a Delaware corporation (the \"Company\") entered into an Agreement and Plan of Merger, dated as of June 18, 2018, as amended (the \"Merger Agreement\"), with Roche Holdings, Inc., a Delaware corporation (\"Parent\" or \"Roche\"), and 062018 Merger Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Parent caused Merger Sub to conduct a tender offer (the \"Tender Offer\") for all of the issued and outstanding shares of common stock, par value $0.0001 per share, of the Company, at a price of $137 per share. On July 31, 2018, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. On July 31, 2018, following consummation of the Tender Offer, Merger Sub merged with and into the Company."},{"field":"shares","element":"transactionShares","label":"F2","text":"The amount reported represents the number of shares sold by the reporting person in connection with the Tender Offer by Roche."}],"balance_after":28709,"source":{"system":"sec-edgar","filing":"0001209191-18-044926","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118044926/doc4.xml","form_type":"4"}},{"id":3872640,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-07-05T16:08:41.000Z","date":"2018-07-02","kind":"sale","acquired":false,"shares":2520,"price":136.66,"value":344383.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person previously reported restricted stock units granted to the reporting person on (1) April 1, 2016 in Table I of the Form 4 filed on April 6, 2016, (2) May 1, 2017 in Table I of the Form 4 filed on May 3, 2017 and (3) April 1, 2018 in Table I of the Form 4 filed on April 3, 2018. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting events related to this securities sale."}],"balance_after":105203,"source":{"system":"sec-edgar","filing":"0001209191-18-041550","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118041550/doc4.xml","form_type":"4"}},{"id":3973031,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2018-04-03T16:11:08.000Z","date":"2018-04-02","kind":"exercise","acquired":false,"shares":2344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on May 21, 2013 and vested in equal quarterly installments over a four-year period beginning on April 1, 2014 until fully vested on January 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":7.12,"expiration_date":"2023-05-21","underlying":"Common Stock","underlying_shares":2344},"source":{"system":"sec-edgar","filing":"0001209191-18-022887","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118022887/doc4.xml","form_type":"4"}},{"id":3973030,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-04-03T16:11:08.000Z","date":"2018-04-02","kind":"sale","acquired":false,"shares":1585,"price":74.88,"value":118684.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.60 to $75.00, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":107723,"source":{"system":"sec-edgar","filing":"0001209191-18-022887","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118022887/doc4.xml","form_type":"4"}},{"id":3973029,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-04-03T16:11:08.000Z","date":"2018-04-02","kind":"exercise","acquired":true,"shares":2344,"price":7.12,"value":16689.28,"ownership":{"direct":true},"balance_after":109308,"source":{"system":"sec-edgar","filing":"0001209191-18-022887","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118022887/doc4.xml","form_type":"4"}},{"id":3973028,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-04-03T16:11:08.000Z","date":"2018-04-01","kind":"grant","acquired":true,"shares":8621,"price":78.75,"value":678903.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.  The restricted stock units vest in equal quarterly installments over a three-year period with the first installment vesting on July 1, 2018."}],"balance_after":106964,"source":{"system":"sec-edgar","filing":"0001209191-18-022887","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118022887/doc4.xml","form_type":"4"}},{"id":4096159,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-01-18T16:03:16.000Z","date":"2018-01-16","kind":"sale","acquired":false,"shares":18021,"price":64.3,"value":1158750.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2017."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.68 to $67.70, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":98343,"source":{"system":"sec-edgar","filing":"0001209191-18-004227","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118004227/doc4.xml","form_type":"4"}},{"id":4112024,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-01-03T17:18:05.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":472,"price":64,"value":30208.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.73 to $64.12, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017.  As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":116364,"source":{"system":"sec-edgar","filing":"0001209191-18-001127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118001127/doc4.xml","form_type":"4"}},{"id":4112023,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2018-01-03T17:18:05.000Z","date":"2018-01-02","kind":"sale","acquired":false,"shares":1392,"price":64,"value":89088.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2018. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.73 to $64.12, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":116836,"source":{"system":"sec-edgar","filing":"0001209191-18-001127","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919118001127/doc4.xml","form_type":"4"}},{"id":4192147,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-10-04T16:02:09.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":663,"price":38.8,"value":25724.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.50 to $38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017.  As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":118228,"source":{"system":"sec-edgar","filing":"0001209191-17-055736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117055736/doc4.xml","form_type":"4"}},{"id":4192146,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-10-04T16:02:09.000Z","date":"2017-10-02","kind":"sale","acquired":false,"shares":1502,"price":38.8,"value":58277.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.45 to $38.80, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":118891,"source":{"system":"sec-edgar","filing":"0001209191-17-055736","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117055736/doc4.xml","form_type":"4"}},{"id":4260866,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-07-07T16:02:07.000Z","date":"2017-07-06","kind":"sale","acquired":false,"shares":452,"price":38.84,"value":17555.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"The reporting person previously reported the restricted stock units granted to the reporting person on May 1, 2017 in Table I of the Form 4 filed on May 3, 2017.  As such, no adjustment to the reporting persons beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":120393,"source":{"system":"sec-edgar","filing":"0001209191-17-044355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117044355/doc4.xml","form_type":"4"}},{"id":4260865,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-07-07T16:02:07.000Z","date":"2017-07-06","kind":"sale","acquired":false,"shares":1246,"price":38.84,"value":48394.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on July 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":120845,"source":{"system":"sec-edgar","filing":"0001209191-17-044355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117044355/doc4.xml","form_type":"4"}},{"id":4260864,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-07-07T16:02:07.000Z","date":"2017-07-06","kind":"sale","acquired":false,"shares":3372,"price":38.84,"value":130968.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on June 30, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $36.85 to $40.05, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":122091,"source":{"system":"sec-edgar","filing":"0001209191-17-044355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117044355/doc4.xml","form_type":"4"}},{"id":4285607,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-12T16:21:11.000Z","date":"2017-06-08","kind":"exercise","acquired":false,"shares":2344,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option was granted on May 21, 2013 and vests in equal quarterly installments over a four-year period beginning on April 1, 2014."}],"balance_after":2344,"derivative":{"exercise_price":7.12,"expiration_date":"2023-05-21","underlying":"Common Stock","underlying_shares":2344},"source":{"system":"sec-edgar","filing":"0001209191-17-039154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117039154/doc4.xml","form_type":"4"}},{"id":4285606,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Stock Option (right to buy)","published_at":"2017-06-12T16:21:11.000Z","date":"2017-06-08","kind":"exercise","acquired":false,"shares":4689,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 7, 2013 and vests in equal quarterly installments over a four-year period beginning on June 7, 2013."}],"balance_after":0,"derivative":{"exercise_price":4.16,"expiration_date":"2023-03-07","underlying":"Common Stock","underlying_shares":4689},"source":{"system":"sec-edgar","filing":"0001209191-17-039154","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117039154/doc4.xml","form_type":"4"}},{"id":4285605,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-06-12T16:21:11.000Z","date":"2017-06-08","kind":"exercise","acquired":true,"shares":2344,"price":7.12,"value":16689.28,"ownership":{"direct":true},"balance_after":125463,"source":{"system":"sec-edgar","filing":"0001209191-17-039154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117039154/doc4.xml","form_type":"4"}},{"id":4285604,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-06-12T16:21:11.000Z","date":"2017-06-08","kind":"exercise","acquired":true,"shares":4689,"price":4.16,"value":19506.24,"ownership":{"direct":true},"balance_after":123119,"source":{"system":"sec-edgar","filing":"0001209191-17-039154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117039154/doc4.xml","form_type":"4"}},{"id":4318296,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-05-16T16:06:28.000Z","date":"2017-05-12","kind":"sale","acquired":false,"shares":1009,"price":33.87,"value":34174.83,"ownership":{"direct":true},"balance_after":118430,"source":{"system":"sec-edgar","filing":"0001209191-17-032611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117032611/doc4.xml","form_type":"4"}},{"id":4335221,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-05-03T16:01:52.000Z","date":"2017-05-01","kind":"grant","acquired":true,"shares":16367,"price":35.8,"value":585938.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units issued pursuant to a Restricted Stock Unit Award Agreement and the Issuer's 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in equal quarterly installments over a three-year period with the first installment occurring on August 1, 2017."}],"balance_after":119439,"source":{"system":"sec-edgar","filing":"0001209191-17-029596","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117029596/doc4.xml","form_type":"4"}},{"id":4358227,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-04-05T16:05:06.000Z","date":"2017-04-03","kind":"sale","acquired":false,"shares":1233,"price":31.96,"value":39406.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on April 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":103072,"source":{"system":"sec-edgar","filing":"0001209191-17-025573","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117025573/doc4.xml","form_type":"4"}},{"id":4377923,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-03-20T16:02:19.000Z","date":"2017-03-16","kind":"sale","acquired":false,"shares":6231,"price":31.67,"value":197335.77,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.53 to $31.95, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."}],"balance_after":104305,"source":{"system":"sec-edgar","filing":"0001209191-17-021681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117021681/doc4.xml","form_type":"4"}},{"id":4498508,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-01-05T16:07:03.000Z","date":"2017-01-04","kind":"sale","acquired":false,"shares":1426,"price":18.49,"value":26366.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on January 1, 2017. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":110536,"source":{"system":"sec-edgar","filing":"0001209191-17-001962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117001962/doc4.xml","form_type":"4"}},{"id":4498507,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2017-01-05T16:07:03.000Z","date":"2017-01-03","kind":"sale","acquired":false,"shares":3256,"price":17.41,"value":56686.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on December 30, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $17.41 to $17.56, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person previously reported restricted stock units granted to the reporting person on July 15, 2015 in Table I of the Form 4 filed on July 17, 2015. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":111962,"source":{"system":"sec-edgar","filing":"0001209191-17-001962","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919117001962/doc4.xml","form_type":"4"}},{"id":4584385,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":82368,"kind":"person","name":"Hesslein Robert W.","position":1,"cik":"0001585018","reported_name":"Hesslein Robert W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP and General Counsel"}}],"security":"Common Stock","published_at":"2016-10-05T16:05:38.000Z","date":"2016-10-04","kind":"sale","acquired":false,"shares":1220,"price":23.65,"value":28853.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of restricted stock units on October 1, 2016. This sale is mandated by the Issuer's election under its equity incentive plans to require the reporting person to fund this tax withholding obligation by completing a \"sell to cover\" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in this Column 4 is a weighted average price. The shares were sold as part of a group sale of shares in multiple transactions at prices ranging from $23.31 to $23.72, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The reporting person previously reported restricted stock units granted to the reporting person on April 1, 2016 in Table I of the Form 4 filed on April 6, 2016. As such, no adjustment to the reporting person's beneficial interest needs to be made to reflect the vesting event related to this securities sale."}],"balance_after":115218,"source":{"system":"sec-edgar","filing":"0001209191-16-144869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488613/000120919116144869/doc4.xml","form_type":"4"}}]}